乳腺癌EphA2和EphrinAl的表达及与临床病理因素的关系

doi:10.13418/j.issn.1001-165x.2017.01.009

中国临床解剖学杂志 ›› 2017, Vol. 35 ›› Issue (1): 43-47.doi: 10.13418/j.issn.1001-165x.2017.01.009

乳腺癌EphA2和EphrinAl的表达及与临床病理因素的关系

张本斯¹，　卞思源¹，　潘云²，　李正军²，　李耀康²

1.大理大学基础医学院解剖学教研室；　2.大理大学附属医院病理科，云南大理 671000

收稿日期:2016-09-22 出版日期:2017-01-25 发布日期:2017-02-22
作者简介:张本斯（1969-），女，云南梁河人，硕士，教授，Tel: (0872)2257104，E-mail: ben-si-zhang@163.com
基金资助:
国家自然科学基金资助项目（81460465 ）

Expression of EphA2 and EphrinAl in the breast carcinoma tissue and its relation to clinicopathological parameters

ZHANG Ben-si¹, BIAN Si-yuan¹, PAN Yun², LI Zheng-jun², LI Yue-kang²

1.Department of Anatomy, College of Preclinical Medicine, Dali University, Dali 671000, China；2.Department of Pathology，Affiliated Hospital of Dali University, Dali 671000, China

Received:2016-09-22 Online:2017-01-25 Published:2017-02-22

摘要/Abstract

摘要：

目的　研究云南白族地区乳腺癌EphA2和EphrinAl的表达及其与临床病理因素的关系。方法　用免疫组织化学(IHC)检测乳腺癌组织中EphA2、EphrinAl的表达，比较各自表达情况与临床病理因素的关系及二者间的相关性。结果　EphA2、EphrinAl主要表达于肿瘤细胞和血管内皮细胞的胞浆和胞膜，呈棕黄色或棕褐色。150 例乳腺癌组织中，EphA2、EphrinAl阳性表达分别为123例、129例，阳性率分别为82%、86%。二者的阳性率与患者年龄无相关性(P>0.05)，而与病理类型、肿瘤大小、淋巴结转移、临床分期和组织学分级有相关性(P<0.05)。浸润性导管癌EphA2和EphrinAl阳性率较导管内癌的高；肿瘤较大组、淋巴结转移组、临床分期较晚者、组织学分级较高组EphA2和EphrinAl的阳性率分别高于肿瘤较小组、无淋巴结转移组、临床分期较早者、组织学分级较低组EphA2和EphrinAl的阳性率。EphA2和EphrinAl阳性染色共同定位于大致相同的肿瘤区域和血管内皮细胞，二者的阳性率有相关性(P<0.05)。结论　EphA2、EphrinAl在乳腺癌高表达，并与其发生发展、侵袭转移及恶性程度有关，有望成为乳腺癌预后评估标志物，为早期诊断和靶向治疗提供新思路。

关键词: 乳腺癌, EphA2, EphrinA1, 临床病理因素

Abstract:

Objective　To investigatethe expression of EphA2 and EphrinAl in the breast carcinoma tissue fromYunnan Dali Bai, Han and other minority women and its relation to clinicopathological parameters. Methods　The expression of EphA2 and EphrinAl in the breast carcinoma tissue was detected by the immunohistochemistry (IHC) method and was compared with theclinicopathological parameters and with each other, respectively.　Results　EphA2 and EphrinA1 were mainly expressed in cytoplasm and membrane of tumor cells and of vascular endothelial cells, showing a tan or brown color. Out of 150 cases of breast cancer tissues, the positive expression of EphA2 and EphrinA1 appeared in 123 and129 cases, and the positive rates of them are 82% and 86%, respectively. The positive expression rates of EphA2 and EphrinAlhave no significant correlation with the patient age (P>0.05), but are correlated statistically with the pathological type, tumor size, lymph node metastasis, clinical stage and histological grade (P<0.05). The positive rates of EphA2 and EphrinAl in the invasive ductal carcinoma are higher than that in the intraductal carcinoma; and the positive rates of EphA2 and EphrinAl in the group with large size, lymph node metastasis, late clinical stage and high histological grade was higher than that in the group with a small size, negative lymph node metastasis, early clinical stage and a low histological grade, respectively. The positive staining of EphA2 and EphrinAliscolocalized in roughly the same tumor areas and vascular endothelial cells.Their distributions were fundamentally unanimous and their positive expression rates were positively correlated (P<0.05).　Conclusion　Over expression of EphA2 andEphrinA1 can be observed in breast carcinoma, which isconcerned with carcinogenesis, development, invasion, metastases and malignant transformation, suggesting that EphA2 and EphrinA1 may be associated with tumour prognosis and could be used as new markers for prognosis evaluation. Our research has laid a theoretical foundation for early diagnosis and targeted therapy of breast carcinoma.

Key words: Breast carcinoma, EphA2, EphrinA1, Clinicopathological parameters

张本斯,卞思源,潘云,李正军,李耀康. 乳腺癌EphA2和EphrinAl的表达及与临床病理因素的关系[J]. 中国临床解剖学杂志, 2017, 35(1): 43-47.

ZHANG Ben-si, BIAN Si-yuan, PAN Yun, LI Zheng-jun, LI Yue-kang. Expression of EphA2 and EphrinAl in the breast carcinoma tissue and its relation to clinicopathological parameters[J]. Chinese Journal Of Clinical Anatomy, 2017, 35(1): 43-47.

参考文献

[1] Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond[J]. Nat Rev Cancer, 2010, 10(3): 165-180.
[2] Holm R, de Putte GV, Suo Z, et al. Expressions of EphA2 and EphrinA1 in early squamous cell cervical carcinomas and their relation to prognosis[J]. Int J Med Sci, 2008, 5(3): 121-126.
[3] LiuY, Yu C, Qiu Y, et a1. Down regulation of EphA2 expression suppresses the growth and metastasis in squamous-cell carcinoma of the head and neck in vitro and invivo[J]. J Cancer Res Clin Oncol, 2012, 138(2): 195-202.
[4] Yuan W, Chen Z, Huang J, et al. Silencing of EphA2 inhibits invasion of human gastric cancer SGC790l cells in vitro and in vivo[J]. Naoplasma, 2012, 59(1): 105-113.
[5] Cui XD, Lcc MJ, Yu GR, et al. EFNAl ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma[J]. Int J Cancer, 20l0, l26(4): 940-949.
[6] Yang P,Yuan W, He J, et al. Overexpression of EphA2, MMP-9, and MVD-CD3 in hepatocellular carcinoma: Implication for tumor progression and prognosis[J]. Hepatol Res, 2009, 39(12):1169-1177.
[7] Merritt WM, Kamat AA, Hwang JY, et al. Clinical and biologocal impact of EphA2 over expression and angiogenesis in endometrial cancer[J]. Cancer Biol Ther, 2011,10(12): 1306-1314.
[8] Lin YG，Han Ly, Kamat A, et a1. EphA2 over expression in endothelial and ovarian cancer cells is strongly associated with critical factors involved in angiogenesis and invasion[J]. Cancer, 2007,10(9): 332-340.
[9] Udayakumar D, Zhang G, Ji Z, et al. EphA2 is a critical oncogene in melanoma[J]. Oncogene, 201l, 30(50): 4921-4929.
[10] Brantley-Sieders DM, Zhuang G, Hicks D, et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling[J]. J Clin Invest, 2008, 118(1):64-78.

乳腺癌EphA2和EphrinAl的表达及与临床病理因素的关系

Expression of EphA2 and EphrinAl in the breast carcinoma tissue and its relation to clinicopathological parameters

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 8

Metrics

本文评价

推荐阅读 0

[1]	张海燕, 孙丽慧, 潘洪明, 李林, 廉洁, 于晶, 郎尉雅. 曲古抑菌素A通过JNK/MAPK信号通路介导乳腺癌MDA-MB-231细胞的凋亡[J]. 中国临床解剖学杂志, 2021, 39(2): 174-181.
[2]	张淑艳,张方,姬颖华. 鼠李素下调Notch-1的表达对乳腺癌MCF-7细胞增殖、侵袭和迁移的调节作用[J]. 中国临床解剖学杂志, 2018, 36(6): 632-636.
[3]	张虎,杜欣娜,庄莹,孙海燕,樊伟平,赵小芳. 乳腺癌中跨膜蛋白81基因高表达不利于患者预后[J]. 中国临床解剖学杂志, 2018, 36(5): 586-589.
[4]	李艳娇,张本斯,李庄,卞思源,杨桂,黄煜. EphA2在乳腺癌中的表达及其与上皮间质转化的关系[J]. 中国临床解剖学杂志, 2018, 36(3): 294-298.
[5]	钮红岺,黄晓萍,刘晓珑,李香芝,肖刚,刘立新. 阿司匹林对血小板诱导的乳腺癌MCF-7细胞上皮间质转化和迁移侵袭能力的影响[J]. 中国临床解剖学杂志, 2017, 35(2): 183-187.
[6]	姜敏,张刚庆,高鹏,李武铭,温建燔,张国伟. 256层CT灌注成像和三维重建对乳腺疾病诊断的临床价值[J]. 中国临床解剖学杂志, 2015, 33(3): 273-277.
[7]	刘春灵, 李晓莉, 杨旭, 高凤兰, 杜华贞. Bmi-1、hTERT在乳腺癌细胞中的表达及与凋亡的关系[J]. 中国临床解剖学杂志, 2014, 32(1): 61-66.
[8]	韩中保, 周羽, 韩扣兰. 乳腺癌根治术保留肋间臂神经对患者术后生存质量的影响[J]. 中国临床解剖学杂志, 2011, 29(5): 591-593.